Tags Posts tagged with "Canada"


0 2214

Canada plans to legalize recreational cannabis before July 1, 2018, and the industry continues to steal headlines as this has created great opportunity for both companies and investors.

Although the opportunity is significant, the process of becoming a licensed medical cannabis producer is very lengthy and expensive. These factors have resulted in the country having a supply and demand issue for the medical cannabis market.

Legal recreational cannabis is supposed to significantly increase the amount of cannabis in demand and Health Canada, which is responsible for the regulation of the medical cannabis market has made it easier for companies to get the required licenses.

Health Canada Streamlines Application Process

In late May, Health Canada announced that it has made some changes to streamline the application process to become a licensed medical cannabis producer. These changes will also increase overall production.

Since the licensing program came into effect in 2013, 45 medical marijuana production licenses have been granted (currently 428 companies applying to become licensed cannabis producers). Some of the changes announced by Health Canada include:

• The hiring of new employees to speed up the application process
• Permitting licensed producers to manage production based on their vault capacity
• Increased freedom to modify and expand their facilities

The biggest change announced by Health Canada pertains to production management. Under the new regulations, licensed producers can increase production within their facility to the maximum they are authorized to store, based on the capacity and security level of their vault(s) or safe(s). This will allow licensed producers to better manage production as necessary to meet demand.

Also, licensed producers will be able to store low-value cannabis waste products in a secure area outside of their vault. This will immediately impact the storage capacity of the LP’s, enabling increased production of finished cannabis products.

An Industry Ready to Bounce Back

Although these companies have been very attractive and profitable investment opportunities, they have been under significant pressure this year and the stocks have come well off its 2017 highs.

Several analysts warned cannabis investors about the massive investor fatigue plaguing cannabis licensed producers. One of the best way to protect yourself against this trend is by focusing on companies that have differentiated itself from its peers. We want to highlight five these companies and explain what and if they have a competitive advantage.

• Canopy Growth: The largest and most diverse licensed producer in Canada. The company has made two large acquisitions in the last two years (Bedrocan and Mettrum Health) and is an attractive stock due to its global presence (Australia, Canada, and Germany), its continued execution and track record, its improving fundamentals, and its management team.
• Aphria: One of the lowest cost producers due to its greenhouse production style. The company has made investments in the burgeoning United States cannabis industry and is levered to states like Arizona and Florida.
• Aurora Cannabis: One of the fastest growing licensed producers and has one of the strongest balance sheets when compared to its peers. Through acquisitions and investments, Aurora has become levered to international markets like Australia and Germany
• Cannabis Wheaton: Operates under a streaming model and does not actually touch the plant. Has secured deals with 17 producers across Canada. The shares have plunged after announcing a new financing deal and we continue to monitor trading after Cannabis Wheaton announced that Hugo Alves was appointed as President and Director of the company.
• Emblem Corp: The company is focused on two major markets. The development of biotech treatments derived from cannabis and the production of high-quality cannabis. Emblem has come off its recent lows and seems to have found a bottom. This is a stock to watch.

Disclaimer: Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. We may buy or sell additional shares of (KWFLF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Authored by: Michael Berger

0 897

There’s a new star in Florida’s medical marijuana industry, and it’s got South Florida connections. This past Wednesday, a company associated with Canadian cannabis operator Aphria and an equity firm Delavaco Group stationed in Fort Lauderdale announced that it has closed on a deal to manage Chestnut Hill Tree Farm, one of seven medical marijuana farmers and distributors in the state.

The deal has been given a green light by the Florida Department of Health.

Under the arrangement, a company operating as Aphria USA will manage the operations of Chestnut Hill Tree Farm, a nursery that does business as CHT Medical. That includes the “cultivation, processing, and dispensing of medical marijuana to patients within the State of Florida” and “the exclusive benefits of the finances from Chestnut’s operation.”

Currently, CHT Medical delivers its medicine to patients. But Aphria plans to significantly increase the size of the company’s operations and establish a network of dispensaries around the state.

“Chestnut is one of a select few licensed producers serving a state with a population over 21 million people,” stated Aphria CEO Vic Neufeld. “It is only the beginning for our plans to be a dominant player in the medical cannabis industry internationally.”

The management agreement allows Delavaco and Aphria to enter into a relatively exclusive market at full force which is on the verge of growing following the November passage of a medical marijuana constitutional amendment. However, it comes at an uncertain time, and amid a flurry of investment and speculation.

The state’s medical marijuana program is about to expand, but as of yet, there are no rules to guide the system, as the Legislature failed to come up with any in its recent session. And it’s unclear whether the state will regulate the number of retail outlets its license-holders can open — a key sticking point that killed a bill this month.

It’s also unclear whether any new licenses will be awarded, although, on Tuesday, an administrative law judge recommended the state issue two new ones, an order the state says it’s still reviewing. Still, Aphria says it remains bullish on the Florida market.

0 1256

1 – Costa Rica Marijuana Policy

A proposal to legalize both medical marijuana and industrial hemp in this Central American republic has been building a great deal of momentum over the last two years, and it seems to have picked up a bit more: The measure currently has the backing of key officials in Costa Rica’s public health system. If the law is enacted, the Department of Health would oversee a regulatory body charged with issuing licenses to farmers and distributors of both cannabis and all-purpose hemp.

2 – Canada Marijuana Policy

Canada’s Prime Minister Justin Trudeau made a vow to decriminalize recreational cannabis in Canada, despite this past 4/20 his administration postponed the issue until later this year. In December, Trudeau’s government stated that it would examine a federal task force’s recommendation for legalizing possession of up to 28 grams of marijuana by adults 18 and older and allowing marijuana sales through licensed pot shops.

3 – Peru Marijuana Policy

Already somewhat pot-friendly, where under a quarter of cannabis is tolerated, this South American nation may be ready to legalize medical marijuana “for the treatment of serious and terminal illnesses.” Earlier this year, President Pedro Pablo Kuczynski’s administration recognized that the push to allow marijuana as medicine came about after law enforcement raided a home in Lima, where parents were cultivating marijuana to create CBD oil for more than 80 children suffering from seizures due to epilepsy.

4 – Ireland Marijuana Policy

A medical cannabis bill was outlined by the activist group People Before Profit was given a green light back in December 2016 by the Dáil Éireann, the lower house of the Irish parliament. The measure would allow physicians to recommend marijuana for a variety of serious sicknesses. Ireland’s health minister confirmed that he would not try to stop the proposed legislation from reaching the committee stage. Legislators have asked the Health Products Regulatory Authority to weigh in on marijuana as medicine, and supporters believe that this will eventually create the way for a medical cannabis program.

5 – Brazil Marijuana Policy

The South American monster has slowly progressed on the issue of marijuana prohibition, partly out of a need to combat drug cartel violence. Personal possession and growing marijuana were decriminalized back in 2006; most recently, Supreme Court Justice Roberto Barroso publicly lamented Brazil’s failed War on Drugs and asked for legalizing marijuana outright. And in January of this year, the health-care regulator Anvisa issued the country’s first license to sell the medical marijuana concentrate Sativex, which is marketed in Brazil as Mevatyl.

0 6172

Although the Canadian cannabis sector offers tremendous upside, investors need to be cautious and focus on companies that have a differentiated strategy.

Back in the gold rush, the miners did not make all the money. It was the ancillary business who profited then and although times have changed, the opportunity has not. We believe that investors need to take a different approach and diversify around the Canadian licensed producers.

We have highlighted three Canadian cannabis stocks that trade in both the United States and Canada which we think have long-term upside due to their respective strategy.

InMed Starting to Catch Fire

InMed Pharmaceuticals Inc. (IMLFF) closed Friday down 5.3% but the shares ended the week up more than 12% off its lows and we think this is a stock investors need to watch. IMLFF broke below its 20 and 50-day moving average on this move lower and we think the shares are set to move higher as trading volume was well below its weekly average on Friday.

Earlier this month, InMed filed a provisional patent application in the United States for a cannabinoid-based topical therapy for glaucoma. The company has taken steps to execute on its strategy and has several event-driven catalysts set to occur in the back half of the year.

Cannabis Wheaton is Changing the Game

One company that looks to have found a bottom and is trending higher is Cannabis Wheaton (CBW.V) (KWFLF). The shares continued to rally on Friday and ended the day up 15% and 16%, respectively. The Canadian symbol is trading at $1.58 while the United States symbol, KWFLF trades at $1.16. Cannabis Wheaton has taken the licensed producer game to a different level and we believe there is significant value in several of its deals.

Earlier this month, Cannabis Wheaton released its roster of streaming deals and its partners include 14 companies based in six provinces across Canada. Of these companies, 2 have sales licenses (Broken Coast and Green Relief), 2 have cultivation licenses, 4 have affirmation letters and 6 are advanced pre-affirmation stage applicants.

Canadian Biotech Breaks Out of Oversold Territory and Set to Rally

Vinergy (VNNYF) traded almost 900,000 shares on Friday and VNNYF rallied well off its lows of the day. We think this massive increase in trading volume is significant and the shares no longer in oversold territory.

We see significant upside to current levels as VIN (the Canadian symbol) remains halted due to closing of the MJ Biopharma deal. Vinergy recently announced that it was increasing the size of its non-brokered private placement due to the high demand and this is a stock investors need to have on their radar

Disclaimer: Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals. Pursuant to an agreement between MAPH and Cannabis Wheaton (KWFLF) we were hired for 30 Days to publicly disseminate information about (KWFLF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for and were paid “0” shares of restricted common shares of Cannabis Wheaton. Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 1 month from 5/1/2017 – 6/1/2017 to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $150,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, KWFLF, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 1195

The medical cannabis market in Canada continues to grab headlines after the country announced plans to legalize recreational cannabis on a national level before July 1, 2018.

This opportunity has created ample opportunities for everyone. From funds to companies, the Canadian legal cannabis market continues to report significant developments.

In April, Horizons ETFs Management launched the first medical cannabis focused exchange traded fund (ETF) called the Horizons Medical Marijuana Life Sciences ETF. The fund trades under the symbol HMMJ on the Toronto Stock Exchange. Although the fund has generated incredible interest, it has not lived up to expectations so far and HMMJ is down 4.1% since it started trading

Passively Managed ETF Doesn’t Work for Cannabis Stocks

Although the Medical Marijuana Life Sciences ETF is designed to be a liquid and investable index of publicly listed companies focused on the cannabis industry, it is not designed to handle volatile periods like the one we have experienced over the last month.

HMMJ is an index (or passively managed) ETF, designed to provide exposure to a basket of North American publicly traded companies with significant business activities in the cannabis industry.

For this reason, we think the ETF may have launched at the complete wrong time. HMMJ started trading right before legislation was tabled by the Canadian federal government. The Canadian cannabis market rallied into this event, but has since pulled back and is look for a bottom.

Don’t End Up in a Liquidity Trap

When it comes to Canadian medical cannabis producers, we are very focused on the recent decrease in trading volume. Across the board (from Aurora to Canopy, from Aphria to Emblem), trading volume has decreased significantly and this is one of the most important metrics to follow.

Trading volume has an immediate impact on a stock’s spread (difference between the buy and sell price) and we continue to closely monitor how this trend continues. If this weak volume trend continues, we expect to see HMMJ trade lower and continue to prefer investing in individual companies at this time.

0 3927

Canada is set to make history this week by tabling legislation that would make the nation the first G-7 country to legalize recreational cannabis.

This development has captured the attention of the market and many investors are focusing on companies levered to this opportunity. We want to highlight two Canadian companies that investors should be monitoring closely.

OrganiGram Announces LOI with Trauma Healing Centers

Organigram Holdings (OGI.V) (OGRMF), a licensed medical cannabis producer in Canada announced that it entered a letter of intent to acquire all the issued and outstanding shares of Trauma Healing Centers Incorporated. Under the terms of the LOI, Organigram will issue 719,425 common shares at $2.78 per share to the company.

Trauma Healing Centers currently services over 3,500 patients across 7 Canadian locations and it has plans to open 7 more locations. The company specializes in medical cannabis assessment and prescribing. Trauma sees patients on a referral basis and offers a multi-disciplinary approach to healing chronic conditions.

Trauma Healing Centers will continue to operate independently by providing referrals based on client need to any licensed producer in Canada. The company is the only organization to have a multi-disciplinary designation with Blue Cross for military and RCMP veteran clients.

We favorable on this development due to the potential synergies between the two companies. Also, the $2 million purchase price is attractive when compared to similar transactions. OrganiGram has rallied off its recent lows and this is a company that should be on every investor’s radar.

Canabo Announces Groundbreaking Results

On Friday, Canabo Medical (CMM.V: TSX Venture) (CAMDF: OTCQB) released the results of an observational study that connected doctor-supervised medical cannabis treatments to a decrease in benzodiazepine reliance among Canadian patients.

Research conducted over the past year revealed that 40% of patients who were prescribed medical cannabis to treat pain and anxiety eliminated the use of benzodiazepines within 90 days. The number of patients that stopped using benzodiazepines increased to 45% within a year of cannabis treatment.


0 3658

With one of the biggest cannabis IPO’s out of the way for the venture market, it’s important to reassess where Emblem Cannabis stands today, and where its headed in the future, in light of all the interim short-term movement. It is often the case, that we find ourselves with too narrow a horizon, and often overlook key fundamentals with all the hearsay of the stock market. I first spoke to Maxim Zavet, President of Emblem, to see where the company stands. I then did a bit of digging on my own. To the goodies!

A Talk With Maxim Zavet, President of Emblem

1. Demand is high, while supply is low, for the medicinal cannabis market (currently). I have heard of stocking problems from other Licensed Producers’ clients. What are you doing to make sure this isn’t the case for Emblem?

Maxim: “We will stop taking registrations to manage supply for our existing customers and only take new registrations when we can supply new customers.”

2. What do you consider your unique value proposition, and how do you intend on translating it into growth?

Maxim: “We have three very distinct verticals 1) High Grade or Premium indoor grown dried flower; 2) Pharmaceutical product development; and 3) Patient education clinics. All of these verticals will create revenue streams and more shareholder value.”

3. John Stewart, and the pharma division of Emblem, have a lot of keen eyes closely watching. When do they begin operations and what will be their primary focus?
Maxim: “We’ve begun our extraction activities under his leadership and hope to be ready to sell Cannabis Oils very soon as the first step, he is also working to create novel formulations and delivery mechanisms from those extractions that we are already producing.”

4. Where do you, as Emblem, expect to be in this space, by the time legalization in Canada is enacted as the law? 2019 likely seems to be the case, where do you expect to be by then as as far as expansion is concerned?

Maxim: “You can expect us to be very competitive in the legalized market with a high quality product at a competitive price. We’ve begun expanding our current facility and will continue expansion as we move closer to legalization. We are getting really good feed back with respect to our branding and we believe that Emblem is going to be a very strong mainstream premium brand.”

5. When supply eventually starts meeting demand, and within the mid-term (let’s say 5 years approx.), if the price of cannabis falls per gram due to that, what safeguards do you have in place to ensure your profit margins aren’t overwhelmingly impacted?

Maxim: “Within the next five years, we feel that if there is downward pressure on the price of cannabis it would be with lower quality greenhouse produced cannabis. This is the case in California where greenhouse product is half the price of indoor premium quality dried flower. Also pharmaceutical like products would not be subject to the same price pressures as dried cannabis would be.”

Favourite Topic: Pesticides

It’s been the concern and cause of a lot of speculation in the industry, as of late. I asked Emblem’s front desk, what they are doing, to protect their product from such pesticides.
The answer: “Hello Hamzah, in regards to the question about pest control, We use organic mites to maintain a healthy plant dynamic so we don’t have to spray our cannabis with chemical pesticides. While Health Canada approves some chemical sprays, we avoid that as they can leave residue on the plant which we do not want to promote.”

Senior Management

Emblem is headed by one of the best senior managements’ in the industry. Gordon Fox, the CEO of Emblem, has practical experience running a successful pharmacy, and handling patients is something he has great familiarity with. Maxim Zavet, the President of Emblem, has traveled the world, studying phenotypes and strains for a living. He is in possession of in-depth knowledge of medicinal marijuana with a long list of contacts around the world. John Stewart, President of Emblem Pharmaceuticals, needs little introduction. He was the man responsible for bringing OxyContin to market during his reign with Purdue Pharma, a drug that rakes in multi-billion dollars annually. Finally, Harvey Sharpio, President of GrowWise Health, served as the CEO for TSX listed Dynacare Inc., a company which was eventually acquired by Laboratory Corp. of America Holdings. This top of the line senior management has invested $6 million of their own, indicating the sort of confidence they have in their operations.

Emblem’s ‘Hybrid’ Double-Edged Sword!

Emblem boasts a model and the experience to back it up, in a way, not many others can. The company has a full-scale grow operation, along with a full-fledged pharma production under way, led by John H. Stewart. The aim is to develop new dosage forms of cannabinoid medication. Gel caps, sprays, trans-dermal patches and pills. Push even a single drug through the market, and this company can fly to new heights. This is the very reason I have been so bullish on Emblem. They also have ‘the’ person to back up their aims in this division.

Production & Expansion

Emblem has invested $11 million in its state-of-the-art facility 60 miles southwest of Toronto, located in Paris, Ontario. The location consists of two buildings, spread across 4.3 acres of land, with a cultivation capacity of 14,500 sqft. Phase 2, subject to and based on initial expentancy, has been completed as of February, 2017, adding 1400kg to their existing 700kg production capacity for a total of 2100kg, for a total of $17.85 million in potential annual revenue, excluding oil sales. Capacity will remain that way until phase 3, which is expected to be complete sometime this year. The scaling out expansion is expected under phase 4, which is expected to be complete by 2018. Emblem plans on having a 12,000kg production capacity by then, with annual potential revenues soaring to $102 million. Emblem, at full production can produce 16,000kg of cannabis, with $136 million in annual revenue.

Greater Profit Margins

Based on phase 2 production, cash cost per gram is set at $1.52, with all-in cost per gram at $2.08 (includes ammortization and packaging). Average sale price is $8.50 per gram, translating into 71% profit margins. Projected operating margin for oil sales is set at a staggering 90%.

Oil Sales

All of this, already, without taking into account oil sales. I expect Emblem to be an industry-leader in this division, fully utilizing their pharma capacities to produce quality product. Within the first 12 months of operations and sales, Emblem expects to rake in $2.9 million in oil sales. The real revelation is in future numbers. For every 100kg of dried flower produced, 20% weight of the remaining plant can be used to produce 10,000 bottles of THC/CBD based oil bottles, translating into $8.1m in potential revenue (harvested 6 times). Simply put, $23.6 million is the potential annual revenue from a single grow room dedicated to oils!

Patient Acquisition

Emblem has out-done it’s own expectations. The company projected an estimate 1,000 patients to have been acquired by March, but that number currently stands just north of 2,000, with 8 days still left in the month. The company has seen a massive growth of 4167% in patient acquisition since operations kicked off. The company has a third prong, apart from cultivation and pharma, which is playing a pivotal role in expediting patient acquisition. GrowWise Health aims to educate the masses about cannabinoid based-treatments, and while doing that, has strategically been positioned to expand the bottom line: growth of the company.

Legal disclaimer: The writer holds a long position in Emblem Corp. (TSXV: ‘EMC.VN’)

And an affiliate of MAPH Enterprises LLC has a share position via private placement of 43,500 shares and 21,750 warrants of Emblem Corp Stock.

0 3384

The Canadian cannabis industry may have received the catalyst it needed…

Yesterday, CBC News reported that the Liberal government will announce legislation next month that will legalize marijuana in Canada by July 1, 2018.

This is a huge announcement as it was one of the main reasons why Justin Trudeau and the Liberal Party won the Canadian general election in 2015.

CBC said it learned that the legislation will be announced during the week of April 10th and will broadly follow the recommendation of a federally appointed task force that was chaired by former liberal Justice Minister Anne McLellan.

A Change of Words

According to the CBC, Parliamentary Secretary to the Minister of Justice Bill Blair briefed the Liberal caucus on the roll-out plan and the legislation during caucus meetings this weekend.

This is a big change from early March when Blair said the Canadian government will take as much time as it needs to correctly implement a legal recreational cannabis program. Blair previously did not suggest a specific time frame because he said it could vary from province-to-province and territory-to-territory

An Industry to Watch

The Canadian medical cannabis industry continues to record double-digit percentage growth on a month-over-month basis and has more than 100,000 patients. There are currently 38 federally licensed medical cannabis producers in Canada and we are favorable on the opportunity that these companies have on hand.

We are favorable on this update and expect to see the market rally higher off this news. Some companies investors should watch include: Cronos Group (MJN.V) (PRMCF), Emblem Corp (EMC.V) (EMMBF), OrganiGram (OGI.V) (OGRMF), Canopy Growth (WEED.TO) (TWMJF), Aphria (APH.V) (APHQF), Aurora Cannabis (ACB.V) (ACBFF), and VinergyRes (VIN.CN) (VNNYF).

Authored by: Michael Berger


Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. An affiliate of MAPH Enterprises LLC owns 43,500 shares of EMBLEM as well as 21,750 Warrants

PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER (http://marijuanastocks.com/content/terms-and-conditions-use/)

1 7832

Canadian licensed medical cannabis producers built off the momentum from Wednesday and benefited from this as it carried into Thursday’s trading session.

These movements are significant because several of these stocks were under pressure on Tuesday and early Wednesday (post-Canopy Growth earnings).

Investors should keep an eye on how this sub-sector continues to trade as we believe it is comprised of some of the highest quality opportunities for investors.

We recapped some of these recent price movements and provided our updated thesis below:

Canopy Growth Corp (WEED.TO: TSX) (TWMJF: OTC) recaptured most of its losses from Tuesday after the shares rallied 3.7% on above-average trading volume. We continue to view Canopy Growth as one of the top long-term cannabis investments due to its leading position in the Canadian medical cannabis market. Canopy Growth recently broke below the $10 level and investor should keep an eye on shares as we continue to see long-term upside to current levels.

OrganiGram Holdings (OGI.V: TSX Venture) (OGRMF: OTC) saw a nice rally yesterday and we will monitor how this continues today. OGI and OGRMF rallied more than 5% and this was a nice change from the recent trend. We will provide updates on any significant price movements today. Stay tuned as we continue to hold cautiously.

Emblem Corp. (EMC.V: TSX Venture) (EMMBF: OTC) continued to rally yesterday and the shares were one of the top performers as they also rallied more than 5%. EMC is trading at $4.17 while EMMBF trades near $3.20. We continue to hold as we are favorable on the long-term outlook. Emblem has a lock up coming up in March and we have started to receive questions about this. Although we expect this to cause a short-term dip, we do not expect it to last long and will keep an eye on any significant price movements leading up to this.

Aurora Cannabis (ACB.V: TSX Venture) (ACBFF: OTC) ended the day up less than 2% and we continue to hold onto the shares. We have contemplated exiting this position and re-entering on weakness, however, we have not decided yet. The reason why we are questioning this holding is due to valuation. When you look at Aurora’s fully-diluted market cap, it is over $1 billion which is significant. We view the risk-reward scenario as balanced here and will keep you updated on how the shares move from here.

Aphria (APH.V: TSX Venture) (APHQF: OTC) edged lower yesterday and this move followed an 18% rally over the last week. APHQF traded as high as $5.15 before ending the day at $4.97 and We continue to see upside to current levels but we may trim the size of our position because of the strength of the recent rally.

CanniMed Therapeutics (CMED.TO: TSX) is trading at $11.95 after the shares edged slightly higher yesterday and we are on the sidelines at current levels. Although we are favorable on the company’s recent execution, the exchange it trades on, and its business model; we are cautious at these levels. We will keep you updated on how the shares trade from here

Cronos Group (MJN.V) recaptured all its losses from Wednesday as the shares rallied approx. 8% yesterday. MJN.V is trading at $2.59 and we are on the sidelines at current levels. We were favorable on MJN after Wednesday’s dip and will monitor how the shares respond today. The company announced a bought deal this week at $2.25 a share and this has caused the shares to trade a little more volatile over the last two trading sessions.

0 3965

Although the Canadian cannabis market has seen incredible growth over the last year, we believe there is a lot of room to run as the legislation to create a recreational cannabis program is scheduled to be introduced this spring.

When looking at growth catalysts for companies levered to the Canadian medical cannabis market, none is more significant than the legalization of recreational cannabis at the federal level. At the United Nations meeting earlier this year, Health Minister Jane Philpott said Canada’s Liberal Party government will introduce a law in the spring to legalize recreational cannabis.

Some Producers to Benefit More than Others

Although recreational cannabis will benefit all licensed producers that are approved to distribute cannabis, some will benefit more than others.

Many licensed producers have been expanding and constructing new facilities to prepare for the increased demand. Investors should focus on companies that are well capitalized, well positioned and well managed.

Private opportunities like The Green Organic Dutchman have generated great interest from investors as the company possesses one of the largest licensed land lots in Canada as well as one of the most attractive valuations when compared to its peers.

This is different than the approach taken by Aphria (APHQF), a licensed producer that recently acquired 200 acres in a separate location in Canada. This acquisition though, is not as attractive as that of The Green Organic Dutchman since Aphria’s property will require its own license from Health Canada.

Companies are Positioning Themselves for Growth

According to Health Canada, if a licensed medical cannabis producer acquires a property that is adjacent to its licensed facility, it does not need to receive a new license.

If the property in not attached or adjacent to the cannabis producer’s licensed property, it will need to apply for and receive a new license from Health Canada.

Although legal recreational cannabis represents a huge market in Canada, these companies must scale the size of their operations to fully capitalize on this opportunity.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements